Navigation Links
Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms
Date:5/7/2008

WASHINGTON, May 7 -- Shire plc(LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented today at a major scientific meeting findings from analyses of pivotal trial results of INTUNIV, a selective alpha-2A-agonist. This compound is an investigational once-daily medication, which is being evaluated for the treatment of the symptoms of Attention Deficit Hyperactivity Disorder (ADHD). The data demonstrated that INTUNIV showed significant efficacy in reducing ADHD symptoms for patients taking the medication when compared to patients taking placebo at all measured time points up to 24 hours postdose.

The U.S. Food and Drug Administration (FDA) issued an approvable letter on June 20, 2007, regarding INTUNIV. Shire is conducting additional clinical work which is designed to enhance the label. Upon approval, INTUNIV will be the first selective alpha-2A receptor agonist indicated for the treatment of ADHD that may provide an important treatment option for patients and physicians.

Summary of Analyses

The pooled analysis evaluated results from these patients on a weight adjusted mg/kg basis from two similarly designed, randomized, double-blind, forced-dose titration, multicenter phase III trials. The primary efficacy measure for both studies was change in the ADHD Rating Scale (ADHD-RS-IV) total score from baseline to endpoint. All patient groups treated with INTUNIV showed significantly greater improvement in ADHD-RS-IV total score from baseline to endpoint than the placebo group (P < .001). The ADHD-RS-IV is a standardized, validated test for assessing symptoms of ADHD and for assessing their response to treatment.

The analysis also studied duration of effect using the Conners' Parent Rating Scale-Revised Short Form (CPRS-R), which is a comprehensive scale that used observer and self-report ratings to help assess ADHD and evaluate be
'/>"/>

Contact: MIchelle Park
212-601-8248
Porter Novelli
Source:Eurekalert

1

GOOD

Page: 1 2

Related medicine news :

1. Anthem Blue Cross and Blue Shield in New Hampshire Announces Unique Enhancement to its ePrescribing Program
2. Shire to present ADHD treatments scientific data at American Psychiatric Assoc. Meeting
3. AUDIO from Medialink and Shire: What It Means to be an Adult With ADHD
4. Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis
5. VIDEO from Medialink and Shire plc: Rare Diseases Must Be Top of the Health Agenda
6. New Hampshire AIDS Group Calls on Huckabee to Disavow His 1992 Statement
7. Shire to Present New Scientific Data on its ADHD Treatments at a Major Psychiatric Meeting
8. New Hampshire: 1st in the Nation Primary State Takes a Stand on E-Prescribing
9. Families Invited to Celebrate Shire Day at Boston Childrens Museum
10. URAC CEO Testifies Before New Hampshire Legislators Regarding New URAC Standards for Pharmacy Benefit Management
11. Exciting New Plan from John Edwards on AIDS; Plan is Bold and Achievable, say New Hampshire Activists

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...ivors of testicular cancer who were treated with c...ffects, including neurological side effects and Ra...d with chemotherapy, according to a new study publ...tional Cancer Institute . , Marianne Brydy, M.D....ity Hospital, in Bergen, Norway, and colleagues co...
(Date:11/25/2009)...-up period was too short to draw definite conclusi...5 (HealthDay News) -- In diabetic patients with bl...fference in outcomes at one year whether patients ...g, British researchers report. , Bypass surgery...ents with coronary artery disease. However, less i...
(Date:11/25/2009)...plagued by neurological symptoms, study finds , ...Neurological side effects are among the potential ...r cancer who were treated with cisplatin-based che...ncluded 1,409 Norwegian men treated for unilateral...part in a follow-up survey conducted from 1998 to ...
(Date:11/25/2009)...ImprovementShownforthe4thStraightYear ,, WASH...CancerAlliance-Georgia(LCA-GA)issuedthe 4thAnnualR...rogressbeingmadeagainstthislethaldiseaseinthestate...),theonlynationalorganizationdedicatedexclusivelyt...iskforlungcancer. ,, (Logo: http://www.newscom....
(Date:11/25/2009)...laced under the skin kill tumor cells, study finds... -- A cancer vaccine delivered in a fingernail-siz...w study reports. , The method uses polymer disk...th tumor-specific antigens and implanted under the...ors. The Harvard University scientists who develop...
Breaking Medicine News(10 mins):Health News:Stenting May Equal Bypass for Diabetic Heart Patients 2Health News:Stenting May Equal Bypass for Diabetic Heart Patients 3Health News:Lung Cancer Alliance-Georgia Issues 4th Annual State-Specific Report Card on Lung Cancer 2
...d a closely monitored surveillance for patients wi...he occurrence of cancer recurrence // compared to ...most of the hospitals. Researchers have found that... treatment and cancer survival. Researchers...
...ghanistan and Nigeria is a polio-endemic country, ...o stop the indigenous polio transmission, accordin...rget remaining strains of the virus has also been ..., namely poliovirus types 1 and 3.In 2006, monoval...
...couraging people from Hong Kong from buying poultr...raditional dish consumed during the // ar New Year...er said Hong Kong residents would ask vendors to k...three from a village in the Shataukok border area ...
...are coming to India for the sake of low priced cos...ucing the waistline, rhinoplasty, and breast impro...osmetic surgeries are conducted in the UK every ye...ic operations performed in 2005. Each breast enlar...
...adversely affected as a result of snoring, accordi...ders Center at Rush University Medical Center // i...the snoring of their husbands. This problem has al...ween the couple when one of them is deprived of sl...
...arch is on the verge of path breaking news that s...cy and schizophrenia. // Reduced vitamin D leve... could spark off the onset of this disorder, acco...el this potential link between Schizophrenia and V...
Other Medicine News:Health News:More People Come To India For Cosmetic Surgery 2Health News:Sunny Side Up - Vitamin-D deficiency linked to Schizophrenia 2
(Date:11/25/2009)...25/PRNewswire/--TheFDAgrantedtraditionalapprovalfo...ereversetranscriptaseinhibitor(NNRTI).INTELENCEist...experiencedadultswhoareexperiencingvirologicfailur...roviral(ARV)agents.Thetraditionalapprovalisbasedon...T-2.INTELENCEiscurrentlymarketedintheU.S.byTibotec...
(Date:11/25/2009)....25/PRNewswire/--RegadoBiosciences,aprivatelyheldc...swithactivecontrolagents,announcedthatDavidMazzo,P...ay21stAnnualHealthCareConferenceattheNewYorkPalace...enat1:10pm(EST)onTuesday,December1andwillincludean...ddevelopmentprogram,theanticoagulantsystem,REG1.Th...
(Date:11/25/2009)...25/PRNewswire-FirstCall/--Abaxis,Inc.(Nasdaq: ABAX...rebloodanalysissystems,announcedtodaythatClintSeve...tthe21stAnnualPiperJaffrayHealthCareConferenceonWe...llbeheldattheNewYorkPalaceHotelinNewYorkCity. ,...ndmarketsportablebloodanalysissystemsforuseinanyve...
Breaking Medicine Technology:U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2HeartSine and Your Safety Company to Donate a Portion of Sales Proceeds to Sudden Cardiac Arrest Foundation 5646 1HeartSine and Your Safety Company to Donate a Portion of Sales Proceeds to Sudden Cardiac Arrest Foundation 5646 2Lilly Surpasses Energy Efficiency Goals and Celebrates Worldwide Energy Day 5643 1Lilly Surpasses Energy Efficiency Goals and Celebrates Worldwide Energy Day 5643 2NGM Biopharmaceuticals Appoints Dr Arthur D Levinson Former Genentech CEO to its Board of Directors 5640 1NGM Biopharmaceuticals Appoints Dr Arthur D Levinson Former Genentech CEO to its Board of Directors 5640 2NGM Biopharmaceuticals Appoints Dr Arthur D Levinson Former Genentech CEO to its Board of Directors 5640 3
...ical data for potential combination,therapies and ...r,ITMN-191 exposure, BARCELONA, Spain, April 11, 2...unced today the presentation of findings from,thre... inhibitor,ITMN-191, alone or in combination with ... European Association for the Study of the,Liver i...
...IRE)--Apr 11, 2007 - New data,supporting the clini... most advanced investigational oral protease inhib... infection, will be presented,at the 42nd Annual M...f the Liver (EASL) in Barcelona this week. In tota...accepted for presentation,at the EASL conference, ...
Other Medicine Technology:InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting 2InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting 3InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting 4Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 2Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 3Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 4Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 5Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 6
LD Lactate –> Pyruvate
Rheumatoid Factor Latex Test (RF)
IgG (sample dilution, 1-shot only) (Liquid)
CRP (Complete Kit with Disposible Cards)
Medicine Products: